Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options.